Vesugen — EU research guide.
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator series with proposed vasoprotective and geroprotective properties, targeting endothelial cell maintenance and vascular aging. It is studied alongside Cardiogen as part of a broader cardiovascular bioregulator research cluster.
What is Vesugen?
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator series with proposed vasoprotective and geroprotective properties, targeting endothelial cell maintenance and vascular aging. It is studied alongside Cardiogen as part of a broader cardiovascular bioregulator research cluster.
What does the research show?
Available research is limited to animal studies and small Eastern European cohorts examining endothelial and vascular aging markers. No independently replicated controlled human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Vesugen is not yet in our price comparison
We expand EU supplier coverage every month.